The Influence of Solid/Solvent Interfacial Interactions on Physicochemical and Mechanical Properties of Ofloxacin

Elkomy, Mohammed H.; El‐Gazayerly, Omaima N.; Abdel‐Rahman, Adel B.

doi:10.1007/s12247-020-09431-7

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, the release of BER from the optimized BER-BLS formulation seemed to be much slower, with a maximum of 40% at 4 h and less than 54% at 8 h. The high affinity of BER for the hydrophobic components in the bilosomal formulation was therefore attributed as a probable explanation for the slow BER release from the optimized bilosomal formulation (Guan et al, 2011 ). The surface-active property of SDC seems ineffective, although treating with surfactants has been reported as a powerful approach to hydrophilizing systems and increases their proclivity for dissolving in aqueous media (Elkomy et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

“…Overall, the data of pharmacokinetic analysis demonstrate that the BLS significantly increases the relative bioavailability of BER-BLS ∼ 6.4-fold compared to BER-SOL. The improved bioavailability might be attributed to greater BLS absorption by Peyer’s patch intestinal M-cells and increased solubility in the presence of lipid and surfactant (Elkomy et al, 2021 ). Additionally, the ultra-deformability of BLS may facilitate absorption through carrier-mediated transmembrane transport (Elkomy et al, 2022 ).…”

Section: Resultsmentioning

confidence: 99%

“…The supernatant was diluted, and the BER quantity was determined using the HPLC method. The following equation was used to calculate EE% (Elkomy et al, 2021 ): …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats

et al. 2022

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus is a life-threatening metabolic disease. At the moment, there is no effective treatment available to combat it. In this study, we aimed to develop berberine-loaded bilosomes (BER-BLS) to boost the oral bioavailability and therapeutic efficacy of berberine, a natural antidiabetic medication. The BER-BLS was fabricated using a thin-film hydration strategy and optimized using a central composite design (face-centered). The average vesicle size, entrapment efficiency, and surface charge of the optimized BER-BLS preparation were 196.5 nm, 89.7%, (−) 36.4 mV, respectively. In addition, it exhibited higher stability and better-sustained release of berberine than the berberine solution (BER-SOL). BER-BLS and BER-SOL were administered to streptozocin-induced diabetic rats. The optimized BER-BLS formulation had a significant hypoglycemic impact, with a maximum blood glucose decrease of 41%, whereas BER-SOL only reduced blood glucose by 19%. Furthermore, the pharmacological effect of oral BER-BLS and BER-SOL corresponded to 99.3% and 31.7%, respectively, when compared to subcutaneous insulin (1 IU). A pharmacokinetic analysis found a 6.4-fold rise in the relative bioavailability of berberine in BER-BLS when compared to BER-SOL at a dosage of 100 mg/kg body weight. Histopathological investigation revealed that BER-BLS is suitable for oral administration. Our data demonstrate that BLS is a potential nanocarrier for berberine administration, enhancing its oral bioavailability and antidiabetic activity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The release behavior of the optimized GS-CBS formula displayed a small initial burst followed by an extended period during the experiment duration (8 h). This initial burst may be explained by the release of GS existing below or at the cubosomal surface [ 42 ] and by the hydrophilic coating imparted by T 80 [ 49 ]. In contrast, the subsequent extended release resulted from the GS being entrapped inside the peculiar cubosomal structure.…”

Section: Resultsmentioning

confidence: 99%

Intranasal Delivery of Granisetron to the Brain via Nanostructured Cubosomes-Based In Situ Gel for Improved Management of Chemotherapy-Induced Emesis

et al. 2022

Self Cite

View full text Add to dashboard Cite

This research aimed to boost granisetron (GS) delivery to the brain via the intranasal route to better manage chemotherapy-induced emesis. Glycerol monooleate (GMO), Poloxamer 407 (P 407) and Tween 80 (T 80) were used to formulate GS-loaded cubosomes (GS-CBS) utilizing a melt dispersion-emulsification technique. GS-CBS were characterized by testing particle diameter, surface charge and entrapment efficiency. The formulations were optimized using a Box–Behnken statistical design, and the optimum formula (including GMO with a concentration of 4.9%, P 407 with a concentration of 10%, and T 80 with a concentration of 1%) was investigated for morphology, release behavior, ex vivo permeation through the nasal mucosa, and physical stability. Moreover, the optimal formula was incorporated into a thermosensitive gel and subjected to histopathological and in vivo biodistribution experiments. It demonstrated sustained release characteristics, increased ex vivo permeability and improved physical stability. Moreover, the cubosomal in situ gel was safe and biocompatible when applied to the nasal mucosa. Furthermore, compared to a drug solution, the nose-to-brain pathway enhanced bioavailability and brain distribution. Finally, the cubosomal in situ gel may be a potential nanocarrier for GS delivery to the brain through nose-to-brain pathway.

show abstract

“…The BER release profile from optimized BER-LC-CTS-NPs and the BER solution is shown in Figure 3 . The optimized nanoparticles showed a sustained release behavior, with a burst release period of 0 to 3 h and a steady release period of 3 to 8 h. The first burst may be attributed to the hydrophilization of the surface of the nanoparticles caused by formation in a polar solvent such as ethanol [ 47 ]. The subsequent sustained release behavior is due to swelling of the hydrophilic molecules of CTS in an aqueous environment [ 48 ].…”

Section: Resultsmentioning

confidence: 99%

Berberine Encapsulated Lecithin–Chitosan Nanoparticles as Innovative Wound Healing Agent in Type II Diabetes

et al. 2021

Self Cite

View full text Add to dashboard Cite

The aim of this research is to formulate a lecithin–chitosan based nanoparticulate system loaded with berberine (BER-LC-CTS-NPs) that could be integrated into a topically applied formulation and assessed for healing wounds in a diabetic animal model. In order to formulate BER-LC-CTS-NPs, soybean lecithin, isopropyl myristate, and berberine dispersed in ethanolic solution were added into an aqueous solution of chitosan dropwise with sonication. We assessed the influence of lecithin amount, chitosan amount, and isopropyl myristate concentration on particle diameter, zeta potential, and entrapment and employed a Box–Behnken statistical design. The resulting optimized BER-LC-CTS-NPs had a mean size of 168.4 nm, a surface charge of 33.1 mV, and entrapment of 82.3%. The optimized BER-LC-CTS-NPs showed a sustained in vitro release profile. Furthermore, the potential of the optimized BER-LC-CTS-NPs integrated into a topical gel formulation for wound healing in streptozocin-induced diabetic rats was assessed. Our findings show that combining chitosan and berberine in the nanoparticles produces a synergistic effect when it comes to wound healing. The optimized nanoparticulate system works by reducing inflammation, inducing blood vessels and fibroblast proliferation, and promoting mature collagen fibers deposition. Based on the experimental results, lecithin–chitosan nanoparticles loaded with berberine have evolved as a promising strategy for accelerating wound the healing process in diabetic patients. However, the clinical merits of the developed system need to be investigated in diabetic patients.

show abstract

The Influence of Solid/Solvent Interfacial Interactions on Physicochemical and Mechanical Properties of Ofloxacin

Cited by 6 publications

References 25 publications

Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats

Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats

Intranasal Delivery of Granisetron to the Brain via Nanostructured Cubosomes-Based In Situ Gel for Improved Management of Chemotherapy-Induced Emesis

Berberine Encapsulated Lecithin–Chitosan Nanoparticles as Innovative Wound Healing Agent in Type II Diabetes

Contact Info

Product

Resources

About